Product review · Updated September 30, 2026
BYOMA Blemish Acne Clearing Cleanser: grouped ingredients and a label gap
The creamy-cleanser description, US acne-treatment record and ingredient-table discrepancy need to remain visible together.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
BYOMA Blemish Acne Clearing Cleanser is described as a creamy facial wash with 2% salicylic acid. Its public formula records are more complicated than that concise headline. The manufacturer groups ingredients by role, while a posted US label supplies separate active and inactive information. Within that label, the structured ingredient table also names GLUCOMANNAN, which is absent from its prose inactive list and the acquired grouped website panel.
This review examines the current product page, the manufacturer’s facial-line context and the US Byoma Ltd record updated in April 2025. It keeps the declarations separate rather than silently combining them. The physical package and complete clinical methods were not acquired. The question is how much the public records establish about this exact cleanser’s composition and barrier-oriented positioning, with the version gap explicitly retained.
In this article
The creamy description identifies a facial cleanser
The manufacturer page identifies Blemish Acne Clearing Cleanser in a 175 mL size and describes a creamy wash. The posted label uses liquid terminology. These descriptions concern one named item, not two verified physical forms. BYOMA’s facial-line account distinguishes the cleanser from other facial products and from body items. That context establishes product-family boundaries rather than permitting a result from a moisturizer, pimple paste or body wash to be transferred here. The format guide explains why a cream-like cleanser should not be confused with a leave-on cream. No firsthand texture assessment has been represented as part of this review.
Drug Facts gives the active a separate purpose
The Byoma Ltd US record, updated April 23, 2025, declares salicylic acid 2% as an acne-treatment active. The FDA Drug Facts guide explains the separate categories for active ingredient, purpose, warnings and inactive ingredients. The FDA cosmetic-labeling guide also discusses the distinct treatment of active and other ingredients where drug and cosmetic labeling overlap. These sources help interpret the record, rather than establishing a compliance audit or individual approval for the cleanser. The active amount is specific declaration evidence. It is not a measurement of every component, proof of the marketed complex’s contribution or a guarantee that the posted label matches every package currently supplied.
Clearamide is a manufacturer-described complex
On the product page, BYOMA presents Clearamide as a patent-pending complex within its barrier-oriented story. The page also names ingredients such as green tea, allantoin and bakuchiol. This is meaningful manufacturer context, but the complex name does not supply a percentage or an independently measured contribution to the finished cleanser’s results. The review has not verified a patent determination or separated a complex’s effect from the rest of the formula. A brand can explain how it positions a blend without that explanation becoming a component-specific trial. The Hero blend review offers another reading question about a named mixture, not a comparison of the products’ clinical performance.
The website organizes ingredients by stated role
BYOMA’s web declaration groups ingredients into described roles. That arrangement should not be read as a descending package list. The posted prose inactive list is a separate record and includes names such as water, glycerin, witch hazel water and stearic acid among others. The FDA’s ingredient-order discussion explains rules with exceptions, including lower-concentration ingredients, color additives and drug actives. It does not allow quantities to be reverse-calculated from either BYOMA panel. The review therefore keeps the grouped presentation and the dated label distinct. A function category is information about the manufacturer’s presentation, not evidence that the corresponding quantity or clinical contribution has been measured.
GLUCOMANNAN remains an unresolved record difference
The structured ingredient table within the posted label includes GLUCOMANNAN. That name is absent from the same record’s prose inactive list and from the acquired grouped website panel. This discrepancy is not resolved by adding the table entry to the prose and calling the result the current formula. Nor does it establish that a reformulation occurred, which version came first or what a particular package contains. The review preserves the disagreement as a documentary gap. The COSRX declaration review provides related reading about another formula question. It does not supply an answer to BYOMA’s specific table-versus-prose difference.
The barrier percentages need their test context
The manufacturer page advertises a 56% hydration increase and up to a 51% barrier improvement in four days. Those figures are attributed to the brand’s clinical summary. The acquired text does not provide the complete sample details, control comparison or measurement methods needed to evaluate the claims fully. They are not a guaranteed response or a promised result timetable for readers. The label also retains a drying and irritation warning concerning another topical acne medication. The mature and dry skin guide offers general reading about that concern. The review keeps quantitative marketing and a label warning together rather than letting one erase the other.
The whole cleanser needs a reconciled package record
The facial-line context and US acne-treatment label support a specific cleanser identity and a declared active. They do not reconcile the grouped website panel, prose inactive list and structured table into one inspected package formula. A current package and relevant complete test records would add information not acquired here. The site’s dryness comparison explains why a percentage and a reassuring format description are only part of a product review. BYOMA’s evidence remains most useful with its boundaries visible: a named creamy cleanser, a 2% declaration, a manufacturer complex story, qualified clinical figures and an unresolved ingredient-record difference, without a clinical ranking or a reader routine.
Sources behind this reading
- Blemish Acne Clearing Cleanser ↗Manufacturer product or exact-product context · Checked September 30, 2026
- DailyMed - BYOMA ACNE CLEARING CLEANSER- salicylic acid liquid ↗Posted manufacturer OTC label; exact captured version · Checked September 30, 2026
- Barrier-Repair Products for Acne-Prone Skin ↗Manufacturer product or exact-product context · Checked September 30, 2026
- FDA: The Over-the-Counter Drug Facts Label ↗Regulator explanation of OTC label fields · Checked September 30, 2026
- FDA Cosmetics Labeling Guide: ingredient-declaration context ↗Regulator selected labeling passages; not a product compliance audit · Checked September 30, 2026